Compare iShares MSCI Japan ETF (EWJ) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Globus Medical Inc. Class A Common Stock — how do they compare? iShares MSCI Japan ETF trades at $94.78 (market cap $23.55B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: iShares MSCI Japan ETF is far larger — about 2.3× Globus Medical Inc. Class A Common Stock's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 57 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EWJ | GMED | |
|---|---|---|
Market Cap | $23.55B | $10.25B |
Volume | 1,896,806 | 1,108,124 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $96.82 |
52-Week Low | $79.49 | $58.33 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.32 with no significant daily movement. Technical indicators show a bullish overall signal with moving averages supporting upward momentum, while oscillators remain neutral. The ETF benefits from Japan's economic developments including recent Bank of Japan rate hikes and fiscal stimulus measures. Support and resistance levels cluster tightly around the current price, indicating potential for breakout movement.
The outlook for EWJ appears cautiously optimistic as Japan navigates monetary policy normalization while maintaining growth stimulus. Investment opportunities include exposure to Japan's AI and semiconductor sectors, though risks persist from yen volatility, rising bond yields, and global macroeconomic pressures. The ETF's performance relative to the S&P 500 in 2026 suggests international diversification benefits.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
